{"entity":{"id":"nct04950322","kind":"trial","name":"A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","aka":[],"tldr":"A phase 3 trial of Retlirafusp alfa run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., active.","summary":"A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer is a phase 3 interventional study registered as NCT04950322 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 737 participants enrolled, started 2021-12-06. Conditions listed: Gastric or Gastroesophageal Junction Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04950322","url":"https://clinicaltrials.gov/study/NCT04950322"}],"tags":["ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["retlirafusp-alfa"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04950322","phase":"3","setting":"A Randomized, Double-Blind, Multi-Center, Phase III Clinical Study of SHR-1701 Plus Chemotherapy Versus Placebo Plus Chemotherapy as Treatment in Patients With Previously Untreated, Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","enrolled":737,"outcomes":[]},"route":"/trials/nct04950322/","neighbours":{"drug":[{"id":"retlirafusp-alfa","kind":"drug","name":"Retlirafusp alfa","route":"/drugs/retlirafusp-alfa/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}